In this issue:
Neoadjuvant DTP vs. trastuzumab emtansine in ERBB2+ breast cancer
Novel targeted agents for ERBB2+ metastatic breast cancer
Chemotherapy complications/outcomes after immediate breast reconstruction
Scaling up treatment and imaging access, and breast cancer survival
Celecoxib does not increase breast cancer DFS
Survival for patients who decline recommended breast cancer treatment
Intense vs. tailored dose-dense chemotherapy in high-risk early breast cancer
Impact of isolated local recurrence on outcomes in early breast cancer after conservation
Continuous vs. intermittent extended adjuvant letrozole for breast cancer
Implications of Z0011 trial application into clinical practice
Please login below to download this issue (PDF)